Skip to Main Content

Paper Details

Phase I/II Trial of the Combination of <sup>177</sup>Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN).
Eur Urol Oncol
22
2021
177Lu, 177Lu PSMA 617, 177Lutetium, 18F-fludeoxyglucose, 68Ga, Anal irritation, CONCLUSIONS, Idronoxil, LuPIN, LuPSMA, LuPSMA-617, Men, NOX66, PATIENT, PSA, PSMA, Prostate Cancer, Prostate specific Membrane Antigen 617, anaemia, cabazitaxel, docetaxel, fatigue, flavonoid, idronoxil, lutetium, mCRPC, men, metastatic castration-resistant prostate cancer, patients, prostate, prostate specific membrane antigen, prostate-specific antigen, prostate-specific membrane antigen 617, taxane, xerostomia
Author NameAffiliation
Arun A AzadSchool of Clinical Sciences, Monash University, Peter MacCallum Cancer Centre, University of Melbourne
Trevor J PughPrincess Margaret Cancer Centre, University Health Network
Trevor J PughPrincess Margaret Cancer Centre, University Health Network
Anthony M JoshuaThe Kinghorn Cancer Centre, St. Vincent's Hospital Sydney, Australia St. Vincent's Clinical School, University of New South Wales, Australia Garvan Institute of Medical Research
  • 1 - 4

Datasets

Release 1.2